TY - JOUR AU - Louis, D. N. AU - Perry, A. AU - Reifenberger, G. AU - Deimling, A. AU - Figarella-Branger, D. AU - Cavenee, W. K. PY - 2016 DA - 2016// TI - The 2016 World Health Organization classification of tumors of the central nervous system: a summary JO - Acta Neuropathol VL - 131 UR - https://doi.org/10.1007/s00401-016-1545-1 DO - 10.1007/s00401-016-1545-1 ID - Louis2016 ER - TY - JOUR AU - Kramar, F. AU - Minarik, M. AU - Belsanova, B. AU - Halkova, T. AU - Bradac, O. AU - Netuka, D. PY - 2016 DA - 2016// TI - Genetic and epigenetic factors affecting development and prognosis of brain Gliomas - a review of cur rent knowledge JO - Ceska a Slovenska Neurologie a Neurochirurgie VL - 79 UR - https://doi.org/10.14735/amcsnn2016400 DO - 10.14735/amcsnn2016400 ID - Kramar2016 ER - TY - JOUR AU - Hainfellner, J. A. PY - 2015 DA - 2015// TI - Translating brain tumor biomarkers into diagnostic use JO - J Neurol Sci VL - 357 UR - https://doi.org/10.1016/j.jns.2015.09.301 DO - 10.1016/j.jns.2015.09.301 ID - Hainfellner2015 ER - TY - JOUR AU - Gao, K. AU - Li, G. AU - Qu, Y. AU - Wang, M. AU - Cui, B. AU - Ji, M. PY - 2016 DA - 2016// TI - TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.6007 DO - 10.18632/oncotarget.6007 ID - Gao2016 ER - TY - JOUR AU - Killela, P. J. AU - Reitman, Z. J. AU - Jiao, Y. AU - Bettegowda, C. AU - Agrawal, N. AU - Diaz, L. A. PY - 2013 DA - 2013// TI - TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal JO - Proc Natl Acad Sci VL - 110 UR - https://doi.org/10.1073/pnas.1303607110 DO - 10.1073/pnas.1303607110 ID - Killela2013 ER - TY - JOUR AU - Nonoguchi, N. AU - Ohta, T. AU - Oh, J. -. E. AU - Kim, Y. -. H. AU - Kleihues, P. AU - Ohgaki, H. PY - 2013 DA - 2013// TI - TERT promoter mutations in primary and secondary glioblastomas JO - Acta Neuropathol VL - 126 UR - https://doi.org/10.1007/s00401-013-1163-0 DO - 10.1007/s00401-013-1163-0 ID - Nonoguchi2013 ER - TY - JOUR AU - Heuling, E. S. AU - Knab, F. AU - Radke, J. AU - Eskilsson, E. AU - Martinez-Ledesma, E. AU - Koch, A. PY - 2017 DA - 2017// TI - Prognostic relevance of tumor purity and interaction with MGMT methylation in Glioblastoma JO - Mol Cancer Res VL - 15 UR - https://doi.org/10.1158/1541-7786.MCR-16-0322 DO - 10.1158/1541-7786.MCR-16-0322 ID - Heuling2017 ER - TY - JOUR AU - Everhard, S. AU - Kaloshi, G. AU - Criniere, E. AU - Benouaich-Amiel, A. AU - Lejeune, J. AU - Marie, Y. PY - 2006 DA - 2006// TI - MGMT methylation: a marker of response to temozolomide in low-grade gliomas JO - Ann Neurol VL - 60 UR - https://doi.org/10.1002/ana.21044 DO - 10.1002/ana.21044 ID - Everhard2006 ER - TY - JOUR AU - Hegi, M. E. AU - Diserens, A. C. AU - Gorlia, T. AU - Hamou, M. F. AU - Tribolet, N. AU - Weller, M. PY - 2005 DA - 2005// TI - MGMT gene silencing and benefit from temozolomide in glioblastoma JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa043331 DO - 10.1056/NEJMoa043331 ID - Hegi2005 ER - TY - JOUR AU - Shu, C. AU - Wang, Q. AU - Yan, X. AU - Wang, J. PY - 2018 DA - 2018// TI - The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival JO - Cancer Med VL - 7 UR - https://doi.org/10.1002/cam4.1666 DO - 10.1002/cam4.1666 ID - Shu2018 ER - TY - JOUR AU - Dubbink, H. J. AU - Atmodimedjo, P. N. AU - Kros, J. M. AU - French, P. J. AU - Sanson, M. AU - Idbaih, A. PY - 2016 DA - 2016// TI - Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC brain tumor group 26951 phase III trial JO - Neuro-oncology VL - 18 UR - https://doi.org/10.1093/neuonc/nov182 DO - 10.1093/neuonc/nov182 ID - Dubbink2016 ER - TY - JOUR AU - Nakagawa, Y. AU - Sasaki, H. AU - Ohara, K. AU - Ezaki, T. AU - Toda, M. AU - Ohira, T. PY - 2017 DA - 2017// TI - Clinical and molecular prognostic factors for long-term survival of patients with Glioblastomas in single-institutional consecutive cohort JO - World Neurosurg VL - 106 UR - https://doi.org/10.1016/j.wneu.2017.06.126 DO - 10.1016/j.wneu.2017.06.126 ID - Nakagawa2017 ER - TY - JOUR AU - Vuong, H. G. AU - Altibi, A. M. A. AU - Duong, U. N. P. AU - Ngo, H. T. T. AU - Pham, T. Q. AU - Chan, A. K. PY - 2017 DA - 2017// TI - TERT promoter mutation and its interaction with IDH mutations in glioma: combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-a meta-analysis of aggregate data JO - Crit Rev Oncol Hematol VL - 120 UR - https://doi.org/10.1016/j.critrevonc.2017.09.013 DO - 10.1016/j.critrevonc.2017.09.013 ID - Vuong2017 ER - TY - JOUR AU - Labussiere, M. AU - Boisselier, B. AU - Mokhtari, K. AU - Stefano, A. L. AU - Rahimian, A. AU - Rossetto, M. PY - 2014 DA - 2014// TI - Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes JO - Neurology VL - 83 UR - https://doi.org/10.1212/WNL.0000000000000814 DO - 10.1212/WNL.0000000000000814 ID - Labussiere2014 ER - TY - JOUR AU - Eckel-Passow, J. E. AU - Lachance, D. H. AU - Molinaro, A. M. AU - Walsh, K. M. AU - Decker, P. A. AU - Sicotte, H. PY - 2015 DA - 2015// TI - Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1407279 DO - 10.1056/NEJMoa1407279 ID - Eckel-Passow2015 ER - TY - JOUR AU - Nguyen, H. N. AU - Lie, A. AU - Li, T. AU - Chowdhury, R. AU - Liu, F. AU - Ozer, B. PY - 2017 DA - 2017// TI - Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy JO - Neuro-oncology VL - 19 ID - Nguyen2017 ER - TY - JOUR AU - Arita, H. AU - Yamasaki, K. AU - Kanemura, Y. AU - Mukasa, A. AU - Nagane, M. AU - Ueki, K. PY - 2017 DA - 2017// TI - A combination of TERT and mgmt improves the prognostication of glioblastomas JO - Neuro-oncology VL - 19 UR - https://doi.org/10.1093/neuonc/nox036.047 DO - 10.1093/neuonc/nox036.047 ID - Arita2017 ER - TY - JOUR AU - Nencha, U. AU - Rahimian, A. AU - Giry, M. AU - Sechi, A. AU - Mokhtari, K. AU - Polivka, M. PY - 2016 DA - 2016// TI - TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas JO - J Neurooncol VL - 126 UR - https://doi.org/10.1007/s11060-015-1999-3 DO - 10.1007/s11060-015-1999-3 ID - Nencha2016 ER - TY - JOUR AU - Spiegl-Kreinecker, S. AU - Lotsch, D. AU - Ghanim, B. AU - Pirker, C. AU - Mohr, T. AU - Laaber, M. PY - 2015 DA - 2015// TI - Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis JO - Neuro-oncology VL - 17 UR - https://doi.org/10.1093/neuonc/nov010 DO - 10.1093/neuonc/nov010 ID - Spiegl-Kreinecker2015 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - PLoS Med VL - 6 UR - https://doi.org/10.1371/journal.pmed.1000097 DO - 10.1371/journal.pmed.1000097 ID - Moher2009 ER - TY - JOUR AU - Tierney, J. F. AU - Stewart, L. A. AU - Ghersi, D. AU - Burdett, S. AU - Sydes, M. R. PY - 2007 DA - 2007// TI - Practical methods for incorporating summary time-to-event data into meta-analysis JO - Trials VL - 8 UR - https://doi.org/10.1186/1745-6215-8-16 DO - 10.1186/1745-6215-8-16 ID - Tierney2007 ER - TY - BOOK AU - Wells, G. AU - Shea, B. AU - O’connell, D. AU - Peterson, J. AU - Welch, V. AU - Losos, M. PY - 2000 DA - 2000// TI - The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses ID - Wells2000 ER - TY - JOUR AU - Higgins, J. AU - Thompson, S. G. PY - 2002 DA - 2002// TI - Quantifying heterogeneity in a meta-analysis JO - Stat Med VL - 21 UR - https://doi.org/10.1002/sim.1186 DO - 10.1002/sim.1186 ID - Higgins2002 ER - TY - JOUR AU - Evangelou, E. AU - Ioannidis, J. P. AU - Patsopoulos, N. A. PY - 2007 DA - 2007// TI - Uncertainty in heterogeneity estimates in meta-analyses JO - BMJ: Brit Med J VL - 335 UR - https://doi.org/10.1136/bmj.39343.408449.80 DO - 10.1136/bmj.39343.408449.80 ID - Evangelou2007 ER - TY - JOUR AU - Park, C. K. AU - Lee, S. H. AU - Kim, J. Y. AU - Kim, J. E. AU - Kim, T. M. AU - Lee, S. T. PY - 2014 DA - 2014// TI - Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.1975 DO - 10.18632/oncotarget.1975 ID - Park2014 ER - TY - JOUR AU - Arita, H. AU - Yamasaki, K. AU - Matsushita, Y. AU - Nakamura, T. AU - Shimokawa, A. AU - Takami, H. PY - 2016 DA - 2016// TI - A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas JO - Acta Neuropathol Commun VL - 4 UR - https://doi.org/10.1186/s40478-016-0351-2 DO - 10.1186/s40478-016-0351-2 ID - Arita2016 ER - TY - JOUR AU - Ceccarelli, M. AU - Barthel, F. P. AU - Malta, T. M. AU - Sabedot, T. S. AU - Salama, S. R. AU - Murray, B. A. PY - 2016 DA - 2016// TI - Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse Glioma JO - Cell VL - 164 UR - https://doi.org/10.1016/j.cell.2015.12.028 DO - 10.1016/j.cell.2015.12.028 ID - Ceccarelli2016 ER - TY - JOUR AU - Picart, T. AU - Barritault, M. AU - Berthillier, J. AU - Meyronet, D. AU - Vasiljevic, A. AU - Frappaz, D. PY - 2018 DA - 2018// TI - Characteristics of cerebellar glioblastomas in adults JO - J Neurooncol VL - 136 UR - https://doi.org/10.1007/s11060-017-2682-7 DO - 10.1007/s11060-017-2682-7 ID - Picart2018 ER - TY - JOUR AU - Picca, A. AU - Berzero, G. AU - Bielle, F. AU - Touat, M. AU - Savatovsky, J. AU - Polivka, M. PY - 2018 DA - 2018// TI - FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas JO - Neurology VL - 90 UR - https://doi.org/10.1212/WNL.0000000000005658 DO - 10.1212/WNL.0000000000005658 ID - Picca2018 ER - TY - JOUR AU - Sasaki, T. AU - Fukai, J. AU - Kodama, Y. AU - Hirose, T. AU - Okita, Y. AU - Moriuchi, S. PY - 2018 DA - 2018// TI - Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai molecular diagnosis network for CNS tumors JO - J Neurooncol VL - 140 UR - https://doi.org/10.1007/s11060-018-2957-7 DO - 10.1007/s11060-018-2957-7 ID - Sasaki2018 ER - TY - JOUR AU - Weller, M. AU - Weber, R. G. AU - Willscher, E. AU - Riehmer, V. AU - Hentschel, B. AU - Kreuz, M. PY - 2015 DA - 2015// TI - Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups JO - Acta Neuropathol VL - 129 UR - https://doi.org/10.1007/s00401-015-1409-0 DO - 10.1007/s00401-015-1409-0 ID - Weller2015 ER - TY - JOUR AU - Ye, N. AU - Jiang, N. AU - Feng, C. AU - Wang, F. AU - Zhang, H. AU - Bai, H. X. PY - 2019 DA - 2019// TI - Combined therapy sensitivity index based on a 13-gene signature predicts prognosis for IDH wild-type and MGMT promoter Unmethylated Glioblastoma patients JO - J Cancer VL - 10 UR - https://doi.org/10.7150/jca.30614 DO - 10.7150/jca.30614 ID - Ye2019 ER - TY - JOUR AU - Arita, H. AU - Yamasaki, K. AU - Nakamura, T. AU - Shirahata, M. AU - Kobayashi, K. AU - Tamura, K. PY - 2016 DA - 2016// TI - TERT promoter mutation is a poor prognostic marker for GBMS and interacts with mgmt methylation status JO - Neuro-oncology VL - 18 UR - https://doi.org/10.1093/neuonc/now212.450 DO - 10.1093/neuonc/now212.450 ID - Arita2016 ER - TY - JOUR AU - Arvold, N. D. AU - Cefalu, M. AU - Wang, Y. AU - Zigler, C. AU - Schrag, D. AU - Dominici, F. PY - 2017 DA - 2017// TI - Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma JO - J Neurooncol VL - 131 UR - https://doi.org/10.1007/s11060-016-2294-7 DO - 10.1007/s11060-016-2294-7 ID - Arvold2017 ER - TY - JOUR AU - Chen, R. AU - Smith-Cohn, M. AU - Cohen, A. L. AU - Colman, H. PY - 2017 DA - 2017// TI - Glioma subclassifications and their clinical significance JO - Neurotherapeutics VL - 14 UR - https://doi.org/10.1007/s13311-017-0519-x DO - 10.1007/s13311-017-0519-x ID - Chen2017 ER - TY - JOUR AU - Franceschi, E. AU - Depenni, R. AU - Paccapelo, A. AU - Ermani, M. AU - Faedi, M. AU - Sturiale, C. PY - 2016 DA - 2016// TI - Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study JO - J Neurooncol VL - 128 UR - https://doi.org/10.1007/s11060-016-2093-1 DO - 10.1007/s11060-016-2093-1 ID - Franceschi2016 ER - TY - JOUR AU - Vuong, H. G. AU - Altibi, A. M. A. AU - Duong, U. N. P. AU - Ngo, H. T. T. AU - Pham, T. Q. AU - Fung, K. M. PY - 2018 DA - 2018// TI - BRAF mutation is associated with an improved survival in Glioma-a systematic review and meta-analysis JO - Mol Neurobiol VL - 55 ID - Vuong2018 ER - TY - JOUR AU - Mansouri, A. AU - Hachem, L. D. AU - Mansouri, S. AU - Nassiri, F. AU - Laperriere, N. J. AU - Xia, D. PY - 2018 DA - 2018// TI - MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges JO - Neuro-oncology VL - 21 UR - https://doi.org/10.1093/neuonc/noy132 DO - 10.1093/neuonc/noy132 ID - Mansouri2018 ER - TY - JOUR AU - Bell, E. H. AU - Zhang, P. AU - Fisher, B. J. AU - Macdonald, D. R. AU - McElroy, J. P. AU - Lesser, G. J. PY - 2018 DA - 2018// TI - Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.1977 DO - 10.1001/jamaoncol.2018.1977 ID - Bell2018 ER - TY - JOUR AU - Alentorn, A. AU - Duran-Pena, A. AU - Pingle, S. C. AU - Piccioni, D. E. AU - Idbaih, A. AU - Kesari, S. PY - 2015 DA - 2015// TI - Molecular profiling of gliomas: potential therapeutic implications JO - Expert Rev Anticancer Ther VL - 15 UR - https://doi.org/10.1586/14737140.2015.1062368 DO - 10.1586/14737140.2015.1062368 ID - Alentorn2015 ER - TY - JOUR AU - Idbaih, A. PY - 2011 DA - 2011// TI - OMICS and biomarkers of glial tumors JO - Rev Neurol VL - 167 UR - https://doi.org/10.1016/j.neurol.2011.07.007 DO - 10.1016/j.neurol.2011.07.007 ID - Idbaih2011 ER - TY - JOUR AU - Xiong, L. AU - Wang, F. AU - Xie, X. Q. PY - 2019 DA - 2019// TI - Advanced treatment in high-grade gliomas JO - J BUON VL - 24 ID - Xiong2019 ER - TY - JOUR AU - Vuong, H. AU - Duong, U. AU - Altibi, A. AU - Ngo, H. AU - Pham, T. AU - Tran, H. PY - 2017 DA - 2017// TI - A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma JO - Endocr Connect VL - 6 UR - https://doi.org/10.1530/EC-17-0010 DO - 10.1530/EC-17-0010 ID - Vuong2017 ER - TY - JOUR AU - Vuong, H. G. AU - Altibi, A. M. AU - Duong, U. N. AU - Hassell, L. PY - 2017 DA - 2017// TI - Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—a meta-analysis JO - Clin Endocrinol (Oxf) VL - 87 UR - https://doi.org/10.1111/cen.13413 DO - 10.1111/cen.13413 ID - Vuong2017 ER - TY - STD TI - Fernandes SG, Dsouza R, Pandya G, Kirtonia A, Tergaonkar V, Lee SY, et al. Role of telomeres and Telomeric proteins in human malignancies and their therapeutic potential. Cancers. 2020;12(7):1901. ID - ref45 ER - TY - JOUR AU - Akincilar, S. C. AU - Unal, B. AU - Tergaonkar, V. PY - 2016 DA - 2016// TI - Reactivation of telomerase in cancer JO - Cell Mol Life Sci VL - 73 UR - https://doi.org/10.1007/s00018-016-2146-9 DO - 10.1007/s00018-016-2146-9 ID - Akincilar2016 ER - TY - JOUR AU - Kim, H. S. AU - Kwon, M. J. AU - Song, J. H. AU - Kim, E. S. AU - Kim, H. Y. AU - Min, K. -. W. PY - 2018 DA - 2018// TI - Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas JO - Pathology-Res Pract VL - 214 UR - https://doi.org/10.1016/j.prp.2018.04.002 DO - 10.1016/j.prp.2018.04.002 ID - Kim2018 ER - TY - JOUR AU - Yu, S. AU - Xu, T. AU - Dai, J. AU - Ma, M. AU - Tang, H. AU - Chi, Z. PY - 2018 DA - 2018// TI - TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma JO - Onco Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S158239 DO - 10.2147/OTT.S158239 ID - Yu2018 ER - TY - JOUR AU - Bu, R. AU - Siraj, A. K. AU - Divya, S. P. AU - Kong, Y. AU - Parvathareddy, S. K. AU - Al-Rasheed, M. PY - 2018 DA - 2018// TI - Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in M iddle E astern papillary thyroid cancer JO - Int J Cancer VL - 142 UR - https://doi.org/10.1002/ijc.31225 DO - 10.1002/ijc.31225 ID - Bu2018 ER - TY - JOUR AU - Hurst, C. D. AU - Platt, F. M. AU - Knowles, M. A. PY - 2014 DA - 2014// TI - Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine JO - Eur Urol VL - 65 UR - https://doi.org/10.1016/j.eururo.2013.08.057 DO - 10.1016/j.eururo.2013.08.057 ID - Hurst2014 ER - TY - JOUR AU - Perry, J. R. AU - Laperriere, N. AU - O’Callaghan, C. J. AU - Brandes, A. A. AU - Menten, J. AU - Phillips, C. PY - 2017 DA - 2017// TI - Short-course radiation plus temozolomide in elderly patients with glioblastoma JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1611977 DO - 10.1056/NEJMoa1611977 ID - Perry2017 ER - TY - JOUR AU - Álvarez de Eulate-Beramendi, S. AU - Álvarez-Vega, M. A. AU - Balbin, M. AU - Sanchez-Pitiot, A. AU - Vallina-Alvarez, A. AU - Martino-González, J. PY - 2016 DA - 2016// TI - Prognostic factors and survival study in high-grade glioma in the elderly JO - Br J Neurosurg VL - 30 UR - https://doi.org/10.3109/02688697.2016.1139049 DO - 10.3109/02688697.2016.1139049 ID - Álvarez de Eulate-Beramendi2016 ER - TY - JOUR AU - Uzuka, T. AU - Asano, K. AU - Sasajima, T. AU - Sakurada, K. AU - Kumabe, T. AU - Beppu, T. PY - 2014 DA - 2014// TI - Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study JO - J Neurooncol VL - 116 UR - https://doi.org/10.1007/s11060-013-1291-3 DO - 10.1007/s11060-013-1291-3 ID - Uzuka2014 ER - TY - JOUR AU - Babu, R. AU - Komisarow, J. M. AU - Agarwal, V. J. AU - Rahimpour, S. AU - Iyer, A. AU - Britt, D. PY - 2016 DA - 2016// TI - Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival JO - J Neurosurg VL - 124 UR - https://doi.org/10.3171/2015.4.JNS142200 DO - 10.3171/2015.4.JNS142200 ID - Babu2016 ER - TY - JOUR AU - Wager, M. AU - Menei, P. AU - Guilhot, J. AU - Levillain, P. AU - Michalak, S. AU - Bataille, B. PY - 2008 DA - 2008// TI - Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study JO - Br J Cancer VL - 98 UR - https://doi.org/10.1038/sj.bjc.6604378 DO - 10.1038/sj.bjc.6604378 ID - Wager2008 ER - TY - JOUR AU - Weller, M. AU - Stupp, R. AU - Reifenberger, G. AU - Brandes, A. A. AU - Bent, M. J. AU - Wick, W. PY - 2010 DA - 2010// TI - MGMT promoter methylation in malignant gliomas: ready for personalized medicine? JO - Nat Rev Neurol VL - 6 UR - https://doi.org/10.1038/nrneurol.2009.197 DO - 10.1038/nrneurol.2009.197 ID - Weller2010 ER - TY - JOUR AU - Gilbert, M. R. AU - Wang, M. AU - Aldape, K. D. AU - Stupp, R. AU - Hegi, M. E. AU - Jaeckle, K. A. PY - 2013 DA - 2013// TI - Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.49.6968 DO - 10.1200/JCO.2013.49.6968 ID - Gilbert2013 ER - TY - JOUR AU - Stupp, R. AU - Hegi, M. E. AU - Mason, W. P. AU - Bent, M. J. AU - Taphoorn, M. J. AU - Janzer, R. C. PY - 2009 DA - 2009// TI - Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(09)70025-7 DO - 10.1016/S1470-2045(09)70025-7 ID - Stupp2009 ER - TY - JOUR AU - Karachi, A. AU - Dastmalchi, F. AU - Mitchell, D. A. AU - Rahman, M. PY - 2018 DA - 2018// TI - Temozolomide for immunomodulation in the treatment of glioblastoma JO - Neuro-oncology VL - 20 UR - https://doi.org/10.1093/neuonc/noy072 DO - 10.1093/neuonc/noy072 ID - Karachi2018 ER - TY - STD TI - Hegi ME, Stupp R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma? Neuro Oncol. 2015;17(11):1425–7. ID - ref60 ER -